This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/stem-cell-derived-rgc-transplantation-from-petri-dish-to-optic-tract

Test your visual field online: https://visualfieldtest.com

Excerpt:

Introduction Glaucoma is a leading cause of irreversible blindness worldwide because the retinal ganglion cells (RGCs) that connect the eye to the brain die and cannot regenerate (). Without RGCs, visual signals from the retina cannot reach brain centers (like the lateral geniculate nucleus and superior colliculus), so vision is lost. Current glaucoma treatments (e.g. lowering intraocular pressure) can protect surviving RGCs but cannot restore those already lost () (). Stem-cell therapy aims to replace lost RGCs by differentiating human pluripotent stem cells (either embryonic stem cells, ESCs, or induced pluripotent stem cells, iPSCs) into RGCs and transplanting them into the eye () (). In principle this could supply an unlimited source of retinal neurons (). But realizing this vision requires surmounting enormous challenges: the new RGCs must survive, grow axons through the eye’s exit (the lamina cribrosa) into the optic nerve, navigate long distances to precise brain targets, form functional synapses, and become myelinated – all in the inhibitory environment of the adult central nervous system. This article reviews the state of the art in deriving RGCs from human stem cells and transplanting them in animal models. We then discuss critical barriers to success – axon extension through the lamina cribrosa, guidance to thalamic and collicular targets, synapse formation, and myelination – as well as safety issues (immune rejection, tumor risk) and delivery methods (intravitreal vs. subretinal injection). Finally, we give a realistic outlook for when “first-in-human” trials in glaucoma might be feasible and what outcome measures they would require. Throughout, we strive for clarity: key terms are kept bold and any technical concepts are explained for a lay audience.Differentiating RGCs from Human Pluripotent Stem Cells Scientists have developed many protocols to turn human ESCs or iPSCs into RGC-like neurons. Typically, stem cells are first guided into a retinal progenitor state using combinations of growth factors and small molecules that mimic eye development (for example, FGF, IGF, BMP, Wnt and Notch pathway modulators) (). Under the right conditions these cells will further differentiate into RGCs, which can be confirmed by RGC markers. Key markers include the transcription factors BRN3B (POU4F2) and ISL1, the RNA-binding protein RBPMS, the neuronal cytoskeletal protein β-III tubulin (TUJ1), and synuclein-γ (SNCG). Indeed, one study showed PSC-derived cultures expressing multiple RGC markers: “transcription factors such as BRN3, ISL1, and SNCG” appeared alongside long neurites, confirming an RGC identity (). These stem-cell RGCs resemble their natural counterparts in gene expression and morphology, extending long processes and firing action potentials. RGCs are not a uniform cell type. Dozens of RGC subtypes exist (e.g. motion-sensitive direction-selective cells, on/off center cells, intrinsically photosensitive melanopsin cells, alpha-RGCs, etc.), each with distinct functions () (). Animal studies have cataloged 30+ RGC subtypes by anatomy and molecular markers (), and evidence suggests humans have on the order of 20 or more subtypes with unique connectivities (). In theory, stem-cell protocols could be tuned to produce specific subtypes by adjusting developmental cues. In practice most current methods aim for a mixed RGC population. Researchers then ve

Support the show